Forum: Kiadis Pharma » Kiadis Pharma juli 2019 |

Kiadis Pharma juli 2019

2.628 Posts, Pagina: « 1 2 3 4 5 6 ... 127 128 129 130 131 132 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Kiadis Pharma to present at upcoming conference in August 2019

Kiadis Pharma to present at upcoming conference in
August 2019
Amsterdam, The Netherlands, July 31, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces it is scheduled to attend the following conference in August 2019.
Cannacord Genuity 39th Annual Growth Conference
August 7-8, 2019, Boston, MA
Management will present on August 7th at 09.00-09.25am EDT and will host meetings.
A live webcast of the presentation will be available here:

An archived replay of the webcast will be available on the Company's website for approximately 90 days following the presentation.
Kiadis Contacts:
Kiadis Pharma:
Maryann Cimino, Manager, Corporate Affairs
Tel. +1 617 710 7305
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514

About Kiadis Pharma
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Kiadis Pharma naar conferentie in Boston
Gepubliceerd op 31 jul 2019 om 18:04 | Views: 0

Gerelateerde instrumenten
Kiadis Pharma 17:35
4,99 -0,02 (-0,30%)

AMSTERDAM (AFN) - Biotechnologiebedrijf Kiadis Pharma is volgende week aanwezig bij de Cannacord Genuity 39th Annual Growth Conference in het Amerikaanse Boston. Dat maakte het bedrijf, dat aan de beurs in Amsterdam genoteerd is, bekend.

Tijdens de conferentie in Boston op 7 en 8 augustus geeft het management van Kiadis Pharma een presentatie. Ook zal de top van het bedrijf enkele ontmoetingen met andere deelnemers organiseren.

sammie1988 schreef op 31 jul 2019 om 18:23:

Dat is mooi , maar dit was al bekend!

Dat was bekend maar wel belangrijk dat Kiadis zich op de kaart zet en laat ook het vertrouwen in Atir zien.

Ze weten ook altijd precies mijn stop los te vinden hoe weinig het ook is.
Dit gebeurd mij telkens maakt niet uit waar ik hem zet 10c eronder of 25c ze pakken hem altijd..
Ik had er dus 1000 nu 500st. Ik doe het rustig aan. Van 5,50 naar 5 had ik alles op stop los er onder gezet dat was achteraf goed.
Die 500 houd ik nu gewoon vast wat er ook gebeurd.
De voorzichtigheid komt ook dat de aex zo hoog staat en dat die elk moment in elkaar kan klappen.

sandman70 schreef op 2 aug 2019 om 09:28:

De voorzichtigheid komt ook dat de aex zo hoog staat en dat die elk moment in elkaar kan klappen.

Of nog een stukje stijgen. Alles kan.
2.628 Posts, Pagina: « 1 2 3 4 5 6 ... 127 128 129 130 131 132 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum


Vertraagd 16-sep-19 17:35
Koers 5,370
Verschil -0,005 (-0,09%)
Hoog 5,380
Laag 5,205
Volume 132.366
Volume gemiddeld 447.018
Volume gisteren 232.598